Send to

Choose Destination
Dan Med J. 2019 Feb;66(2). pii: A5527.

Clostridium histolyticum as first-line treatment of Dupuytren's disease.

Author information




The optimal minimal invasive treatment for Dupuytren's contractures (DC) remains debated. The aim of this study was to evaluate the effect of Clostridium histo-lyticum collagenase after 1-4 years of follow-up. The out-comes of this study were 1) overall improvements in degrees from baseline to follow-up; 2) contraction recurrence defined as an extension deficit above 20°, and 3) Hurst endpoint defined as an extension deficit below 5°.


All patients treated with C. histolyticum collagen-ase at the Regional Hospital Horsens from 2013 to 2016 with a minimum of one year of follow-up due to DC were included. The range of motion of the affected finger joint was measured before and immediately after injection and at follow-up. Specific information regarding known co-morbidities to DC was acquired.


A total of 112 metacarpophalangeal (MCP) and 47 proximal interphalangeal (PIP) joints were included. Total improvement in the range of motion for MCP and PIP joints were 43° and 16°, respectively. The recurrence rate was 9% for MCP joints and 70% for PIP joints. 73% of MCP joints and 9% of PIP joints achieved the Hurst endpoint. 92% of the patients were willing to repeat treatment.


Collagenase is a viable first-line treatment for MCP joint contractures. However, results are inferior in the PIP joint.


This work was supported by the The Scientific Foundation of Horsens Regional Hospital (grant number 00.06-G01-1-17).


ClinicalTrials ID NCT03331926.


Supplemental Content

Full text links

Icon for Danish Medical Association
Loading ...
Support Center